Essentially the co-development of testing products to enhance the value and efficacy of a therapeutic, companion diagnostics is widely seen as an important growth strategy in both the diagnostic and pharmaceutical industries. It is envisioned as a pathway to personalized medicine, where the right therapeutic is selected for the right patient. Personalized medicine is one of the key trends in healthcare, and it's no surprise that there is great enthusiasm in many quarters of the in vitro industry, pharmaceutical companies and the investment community about companion diagnostics. But will the concept work in the fashion that the industry is envisioning? Who will succeed and with what strategy? How much can companies expect to earn in this field? What strategies should companies adopt to thrive in this market?
In this report, Kalorama Information analyst Kenneth Krul, PhD. brings a real-world view to the concept of companion diagnostics and the likely scenario given market conditions. He addresses the myriad challenges that diagnostic and pharmaceutical companies will face in this endeavor. He outlines strategies that will be more successful. His analysis includes:
The following companies and their efforts in companion diagnostics are profiled in this report:
Companion Diagnostics Markets (A Realistic Assessment of the Opportunities,...
Or leave us a message and we'll call you back!
Receive bi-weekly email alerts for new market research.